GlassScriptPhysician profile
David S Wilson
NPI 1770592727
$688,593.60
in general payments reported to CMS, 2019-2025
28 companies · $49K in 2025
The $49K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385K · 2020: $32K · 2021: $55K · 2022: $65K · 2023: $46K · 2024: $57K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $146K · Food and Beverage: $5,524 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $146,085.00 |
| Food and Beverage | $5,523.59 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon Endo-Surgery INC. | $384,212.71 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $206,611.56 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $95,209.05 | 2019-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Ethicon INC. | $588.93 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $368.76 | 2022-2023 | Dupixent |
| Body Vision Medical INC. | $330.26 | 2023-2024 | Lungvision |
| Amgen INC. | $232.08 | 2023-2024 | Tezspire |
| Grifols USA, LLC | $192.62 | 2019-2025 | Prolastin-C Liquid |
| Csa Medical, INC | $170.21 | 2019 | |
| Ambu INC. | $148.20 | 2021 | |
| Janssen Research & Development, LLC | $91.28 | 2019 | |
| Philips North America LLC | $63.02 | 2019-2022 | |
| United Therapeutics Corporation | $49.88 | 2021 | |
| Medical Device Business Services, INC. | $40.69 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.59 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $37.28 | 2024 | |
| Genentech USA, INC. | $28.51 | 2019-2021 | |
| Genzyme Corporation | $25.36 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $24.10 | 2019 | |
| Baxter Healthcare | $17.81 | 2022 | |
| Insmed, INC. | $17.38 | 2025 | Brinsupri |
| Electromed, INC. | $15.13 | 2023 | Smartvest |
| Mallinckrodt Hospital Products INC. | $14.38 | 2020 | |
| Resmed Corp | $13.88 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $13.48 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.62 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.34 | 2019 | |
| Circassia INC. | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.